| Document |
Document Title |
|
WO/2018/213420A1 |
Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside ...
|
|
WO/2018/212236A1 |
Provided is a novel oligonucleotide production method using a nucleoside or oligonucleotide that can be isolated easily and has high storage stability. An oligonucleotide production method including a coupling step of reacting a 5'-hydro...
|
|
WO/2018/208667A1 |
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as induc...
|
|
WO/2018/207950A1 |
Provided are a novel class A GPCR antagonist, a production method for same, and a novel compound which interacts with the binding site of a class A GPCR Na+- water molecule cluster. A compound, or a salt thereof, having a structure in wh...
|
|
WO/2018/208727A1 |
Nucleoside and nucleotide compounds and analogues, and pharmaceutically acceptable compositions thereof, as inhibitors of CD73 for the treatment of diseases or disorders associated with CD73 activities, especially cancers, and methods of...
|
|
WO/2018/204784A1 |
Methods of minimizing hook effect interference in an immunoassay are disclosed. Also disclosed are reagents, kits, and immunoassay devices that may be utilized in accordance with the method.
|
|
WO/2018/203099A1 |
The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type r...
|
|
WO/2018/200357A1 |
Provided herein are methods and compositions related to treating and/or preventing infertility, improving fertility and/or increasing lactation in a subject by administering to the subject (e.g., orally administering to the subject) a co...
|
|
WO/2018/200356A1 |
Provided herein are methods and compositions related to treating and/or preventing kidney related diseases and disorders, treating and/or preventing acute kidney injury, and for improving kidney health in a subject by administering to th...
|
|
WO/2018/200859A1 |
Multitargeted pyrimidlne nucleoside carbamates, substituted with fluorine at both the base and the sugar moieties, are disclosed (see Formula I) where R =linear or branched alkyl (C1-7); R' = H, hydroxy protecting group; R" = H, phosphat...
|
|
WO/2018/199048A1 |
[Problem] To provide, in place of injected agents (nucleoside-based anticancer agents or antivirus agents) clinically used as therapeutic drugs for cancer or virus infections, a medicine that has high stability with respect to various hy...
|
|
WO/2018/194958A1 |
A method for determining in a sample, by mass spectrometry, the presence, absence, or amount of one or more analytes is described herein. The run time is less than six minutes. The method includes subjecting the sample to an ionization s...
|
|
WO/2018/192502A1 |
Provided in the present invention are an antiviral precursor drug nucleoside cyclophosphate compound based on liver-specific delivery (LSD) technology and the use thereof, and in particular, provided in the present invention are a compou...
|
|
WO/2018/189546A1 |
The present invention relates to chemical linkers and protecting groups, compounds and compositions containing the chemical linkers or protecting groups, and intermediates and processes that can be used to prepare them. The chemical link...
|
|
WO/2018/187540A1 |
The invention provides a compound of formula (I): wherein R is as described herein. The invention also provides a process for the preparation of the compound.
|
|
WO/2018/178679A1 |
The invention provides a combination comprising: (i) a compound of formula (Io) : (Io) or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a co...
|
|
WO/2018/175436A1 |
Provided herein are methods for template-independent synthesis of oligonucleotides using a DNA polymerase. Also provided are methods for template-directed synthesis of oligonucleotides and for sequencing of nucleic acids using DNA polyme...
|
|
WO/2018/160088A1 |
The present invention relates to a prodrug and the use thereof to treat patients suffering from viral and cancerous diseases. The present prodrug provides inhibition of NS5B HCV polymerase, HBV DNA polymerase and HIV-1 reverse transcript...
|
|
WO/2018/160089A1 |
The present invention relates to a prodrug and to the use of same to treat the hepatitis C virus in patients. A prodrug of general formula 1, a stereoisomer thereof, an isotopically enriched analogue, a crystalline or polymorphic form.
|
|
WO/2018/155451A1 |
The purpose of the present invention is to provide: a nucleic acid compound represented by formula (I) or formula (II), said nucleic acid compound hardly forming a non-Watson-Crick base pair; and an oligonucleotide which comprises the nu...
|
|
WO/2018/152453A1 |
Provided herein are compounds useful for the treatment of cancer.
|
|
WO/2018/152450A1 |
Provided herein are compounds useful for the treatment of cancer.
|
|
WO/2018/149945A1 |
The present invention relates to a compound bearing at least two fucose moieties for its use as a drug in the prevention or treatment of infections caused by Aspergillus spp, said compound having a molecular weight comprised from 0.6 to ...
|
|
WO/2018/143403A1 |
Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce au...
|
|
WO/2018/144778A1 |
The disclosure relates to synthetic thermostable polynucleotides, as well as methods of synthesizing and delivering the polynucleotides.
|
|
WO/2018/144854A1 |
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and thera...
|
|
WO/2018/144088A1 |
Disclosed is a therapeutic regimen which includes S-adenosyl methionine, or a salt thereof; folic acid, or a metabolite thereof, or a salt thereof; and a compound of Formula (I), or salt thereof, useful in the treatment of a variety of c...
|
|
WO/2018/138508A1 |
The invention relates to methods of synthesizing polymers, biopolymers, and nucleic acids, to immobilised dNTP/NTPs and kits comprising said immobilised dNTP/NTPs for use in said methods of nucleic acid synthesis.
|
|
WO/2018/140734A1 |
Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N 6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, ...
|
|
WO/2018/140270A1 |
Tunicamycin related compounds having an acyl chain double bond reduced and/or having an acyl chain double bond and an uracil ring double bond reduced are described as well as methods of making these tunicamycin related compounds. These t...
|
|
WO/2018/132890A1 |
There is described herein, a method for inducing Tc22 lineage T cells from a population of CD8+ T cells, the method comprising: a) providing a population of CD8+ T cells; b) activating the population; and c) culturing or contacting the p...
|
|
WO/2018/133854A1 |
Provided are a kind of nucleoside analogue compounds, and compositions comprising these compounds and pentostatin, their use for modulating circadian rhythm, preferably, for shifting circadian phase, and methods for modulating circadian ...
|
|
WO/2018/134343A1 |
The present invention is directed to a compound of formula (III), its preparation and to its use for the preparation of a compound of formula (IV). The present invention hence is directed to a process for the preparation of compound of f...
|
|
WO/2018/131950A1 |
The present invention relates to a carbocyclic nucleoside derivative represented by chemical formula A or a pharmaceutically acceptable salt thereof, and an antiviral agent comprising the same.
|
|
WO/2018/122157A1 |
The present invention provides for stable nucleotide reagents used for nucleic acid amplification by PCR and RT-PCR (Reverse Transcriptase-PCR) that comprises modified nucleoside polyphosphates. The present invention also provides for me...
|
|
WO/2018/121678A1 |
The present invention relates to a prodrug of antiviral nucleoside analogues, and a composition and use thereof, and specifically relates to a prodrug of anti-hepatitis C virus nucleoside analogues. The prodrug can be used as an inhibito...
|
|
WO/2018/113710A1 |
Provided in the present invention is a method for preparing a β-nucleoside compound, comprising the steps of: 1) performing a silylation reaction of a nitrogenous base or an analogue thereof in the presence of TMSOTf to obtain the nitro...
|
|
WO/2018/118664A1 |
Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein...
|
|
WO/2018/115309A1 |
The present invention relates to methods for preparation of glyco-conjugated proteins and in particular to processes for preparation of sugar-nucleotides and modified sugar-nucleotides.
|
|
WO/2018/119117A1 |
The present disclosure provides cyclic dinucleotides (CDNs), and methods of preparing and using the same. The subject methods can include contacting a CDN producing-enzyme with a precursor of a CDN under conditions sufficient to convert ...
|
|
WO/2018/113592A1 |
The present invention relates to a solid form of a compound of formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involv...
|
|
WO/2018/113652A1 |
Provided in the present invention are a compound as shown in formula (I), a pharmaceutical composition comprising same, and a preparation method and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse tran...
|
|
WO/2018/119284A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2018/110643A1 |
[Problem] To provide a nucleoside derivative having antiviral activity against at least HBV and also having low toxicity for host cells. [Solution] A nucleoside derivative represented by general formula (1). In formula (1), R is an optio...
|
|
WO/2018/110591A1 |
The present invention makes it clear that a nucleoside derivative which shows excellent antiviral activity against HBV and which has low cytotoxicity can be obtained by substituting specific functional groups at each of positions 2, 6, a...
|
|
WO/2018/110678A1 |
[Problem] To provide a nucleoside that is more practical for RNA pharmaceuticals and other applications and a use therefor. [Solution] A nucleoside derivative indicated by formula (1) or (2) or a salt thereof. (In formula (1), R1 indicat...
|
|
WO/2018/107377A1 |
A purification process of NADPH is used for purifying a crude NADPH product obtained by biocatalytic preparation. The present invention resolves the technical problems of existing ion exchange resin methods having low yields and low puri...
|
|
WO/2018/109416A1 |
The invention relates to novel molecules pertaining to the family of nucleoside analogues, with an antiproliferative activity. The invention also relates to the method for the synthesis of said molecules and to the application thereof in...
|
|
WO/2018/104856A1 |
A process of obtaining a purified geometric isomer of an unsaturated macrocyclic compound is disclosed herein. The process is effected by contacting an ion exchange medium comprising silver ions with a mixture comprising at least one geo...
|
|
WO/2018/100137A1 |
The invention relates to nucleoside triphosphate and nucleoside triphosphate analogue prodrugs. It is an object of the present invention to provide improved nucleoside triphosphate or nucleoside triphosphate analogue prodrugs. To achieve...
|
